Metformin and heart failure: Innocent until proven guilty

Diabetes Care

Volumn 28, Issue 10, 2005, Pages 2585-2587

  Inzucchi, Silvio E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOOP DIURETIC AGENT; METFORMIN; PHENFORMIN; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; INSULIN RESISTANCE; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE;

DIABETES MELLITUS, TYPE 2; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 25644440023     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.10.2585     Document Type: Editorial

References (30)

1. UK Prospective Diabetes Study Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
2. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
3. Cusi K, DeFronzo RA: Metformin: a review of its metabolic effects. Diabetes Rev 6:89-131, 1998
4. Hundal RS, Inzucchi SE: Metformin: new understandings, new uses. Drugs 63: 1879-1894, 2003
5. Nathan DM: Clinical practice: initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349, 2002
6. Colwell JA: Is it time to introduce metformin in the United States? Diabetes Care 16:653-655, 1993
7. Glucophage [package insert]. Princeton, NJ, Bristol-Myers Squibb, 1995
8. Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, Benet LZ, Karam JH: Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 36:1012-1021, 1996
9. Chang CT, Chen YC, Fang JT, Huang CC: Metformin-associatecl lactic acidosis: case reports and literature review. J Nephrol 15:398-402, 2002
10. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA: Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338:265-266, 1998
11. Sulkin TV, Bosman D, Krentz AJ: Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 20: 925-928, 1997
12. Holstein A, Nahrwold D, Hinze S, Egberts EH: Contra-indications to metformin therapy are largely disregarded. Diabet Med 16:692-696, 1999
13. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD, DARTS/MEMO Collaboration: Contraindications to metformin therapy in patients with type 2 diabetes: a population-based study of adherence to prescribing guidelines. Diabet Med 1:483-488, 2001
14. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, Krumholz HM: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 290:81-85, 2003
15. Salpeter S, Greyber E, Pasternak G, Salpeter E: Risk of fatal and non-fatal lactic acidosis with metformin in type 2 diabetes. Arch Intern Med 163:2294-2602, 2003
16. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB: The incidence of congestive heart failure in type 2 diabetes. Diabetes Care 27:1879-1884, 2004
17. Gustafsson I, Brendorp B, Seibaek M, Burchardt H, Hildebrandl P, Kober L, Torp-Pedersen C, Danish Investigators of Arrhythmia and Mortality on Dofetilde Study Group: Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 43: 771-777, 2004
18. Piccini JP, Klein L, Gheorghiade M, Bonow RO: New insights into diastolic heart failure: role of diabetes mellitus. Am J Med 116 (Suppl. 5A):64S-75S, 2004
19. Parsonage W, Hetmanski D, Cowley A: Differentiation of the metabolic and vascular effects of insulin in insulin resistance in patients with chronic heart failure. Am J Cardiol 89:696-703, 2002
20. Coats AJS, Anker S: Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol 35 (Suppl. 4):S9-S14, 2000
21. Stratton, Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
22. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
23. Smooke S, Horwich TB, Fonarow GC: Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149:168-174, 2005
24. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345-2351, 2005
25. Johnson JA Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with metformin use compared to sulfonylurea monotherapy in type 2 diabetes mellilus. Diabetes Care 25:2244-2248, 2004
26. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583-590, 2005
27. Taegtmeyer H, McNulty P, Young ME: Adaptation and maladaplalion of the heart in diabetes. Part I: general concepts. Circulation 105:1727-1733, 2002
28. Young LH, Russell RR, Yin R, Caplan MJ, Ren J, Bergeron R, Shulman GI, Sinusas AJ: Regulation of myocardial glucose uptake and transport during ischemia and energetic stress. Am J Cardioi 83:25H-30H, 1999
29. Jones GC, Macklin JP, Alexander WD: Contraindications to the use of metformin: evidence suggests that it is time to amend the list (Editorial). BMJ 326:4-5, 2003
30. Misbin RI: The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 27:1791-1793, 2004